APRIL 22, 2025

Biophytis targets mobility restoration in patients with obesity Biophytis strentghens its position as one of the leading players in preserving muscle function in patients with obesity treated with GLP-1 therapies. While these treatments are revolutionizing obesity care by delivering significant weight loss, they also induce a concerning loss of muscle mass, which can compromise patients’ mobility, strength, and quality of life. It is now essential to move beyond viewing weight loss purely in quantitative terms and focus instead on the quality of weight loss—meaning the reduction of fat mass while preserving muscle mass and improving functional mobility. The development of

Read the press release »

APRIL 9, 2025

Biophytis Confirms the Launch of the Phase 2 OBA Clinical Trial in Obesity Biophytis confirms the launch of the Phase 2 OBA clinical study in obesity, expected to begin as early as possible in 2025. Following the recent €2.6 million capital increase announced on March 26, 2025, and promising preclinical results presented at the 15th International Conference on Frailty and Sarcopenia in Toulouse, Biophytis will continue the clinical development of BIO101 in obesity. The goal is to evaluate the efficacy and safety of BIO101 in reducing muscle strength loss caused by GLP-1 agonists in patients with obesity. As a reminder,

Read the press release »

MARCH 28, 2025

Biophytis announces the settlement and delivery of its €2.6 million private placement NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES OF AMERICA, CANADA, AUSTRALIA, JAPAN AND SOUTH AFRICA Biophytis announces today the settlement and delivery of its private placement in the amount of €2,599,979.72 (including the issuance premium), carried out through the issuance, without preferential subscription rights, of (i) 4,307,614 new ordinary shares of the Company (the “New Shares”), each accompanied by a share subscription warrant (a “Warrant”) (together with the New Share, the “ABSA”), and (ii) 5,692,308 prepaid subscription warrants (the “Prepaid Warrants”), each also accompanied by

Read the press release »

MARCH 26, 2025

Biophytis announces the successful completion of a €2,6 million private placement Capital increase of a total amount of approximately €2,6 million in gross proceeds by issuing 4,307,614 new shares, each with one share warrant attached, at €0,26 per unit, and 5,692,308 pre-funded warrants, each with one share warrant attached, at €0,25 per pre-funded unit; Gross proceeds include €2 million from Armistice, and approximately €0,6 million from a limited number of other qualified investors. Settlement-delivery of the new shares and share warrants expected on March 28, 2025. NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES OF AMERICA, CANADA, AUSTRALIA,

Read the press release »

MARCH 24, 2025

Biophytis announces new non-clinical data further supporting its mission to pioneer the restoration of mobility in patients with obesity 96% of patients with obesity report experiencing muscle strength impairment, affecting their mobility. New preclinical study results: The combination of BIO101 and GLP-1 induced muscle strength and mobility restoration in animal model. Biophytis announces new preclinical results for its investigational drug BIO101. These results were presented for the first time last week at the 15th International Conference on Frailty and Sarcopenia Research in Toulouse. Key findings on BIO101 in obesity include: In this newly reported preclinical study BIO101, in combination with

Read the press release »

MARCH 17, 2025

Biophytis revolutionizes sarcopenia Biophytis is excited to announce a world premiere: the publication of the Phase 2 clinical trial SARA-INT in the Journal of Cachexia, Sarcopenia and Muscle (JCSM), the key reference journal for research on sarcopenia. Key BIO101 Attributes from the SARA INT Trail include: Promising Efficacy: BIO101 350mg bid demonstrates a clinically meaningful improvement in the 400-meter walk test (400MWT), primary endpoint of the study Excellent Safety: At all doses, BIO101 shows a very good safety profile with no Serious Adverse Events (AE) related to the product Greater Efficacy in high-risk population: Nominally significant treatment effect versus placebo

Read the press release »

MARCH 6, 2025

Biophytis announces its participation to the BIO-Europe Spring 2025 in Milan Biophytis is pleased to announce its participation in BIO-Europe Spring 2025, taking place in Milan, Italy, from march 17 to 19, 2025. Edouard Bieth, our Chief Business Officer, will take part in numerous meetings throughout the conference. As one of the most innovative biotechnology companies in aging, Biophytis is looking forward to connecting with industry leaders, partners and innovators to discuss the future of our lead drug candidate, BIO101 in obesity and sarcopenia. About BIO-Europe Spring In 2024, BIO-Europe brought together over 3,400 participants from 59 countries and more

Read the press release »

FEBRUARY 25, 2025

Biophytis announces its participation in the 15th International Conference on Frailty and Sarcopenia Research (ICFSR) Biophytis announces its participation in the International Conference on Frailty and Sarcopenia Research & Geroscience Task Force (ICFSR), taking place from March 12 to 14 in Toulouse. The International Conference on Frailty and Sarcopenia Research (ICFSR) is a leading annual scientific event dedicated to accelerating the development of clinical trials for frail older adults. It brings together researchers, clinicians, and industry professionals to share their experiences and advances in the prevention of frailty, disability, and dependency. All presented research undergoes a rigorous peer-review process by

Read the press release »

FEBRUARY 11, 2O25

Biophytis unveils its outlook strategies for 2025 Biophytis today unveils its strategic outlook for the year 2025. Biophytis has improved its competitive positioning and fundamentals in recent months, paving the way for accelerated execution of its strategic roadmap: Launch of the OBA clinical development program for the treatment of obesity, Strategic licensing agreement signed with Blanver, Entry into exclusive negotiations with a major Chinese pharmaceutical company, Conclusion of a co-development agreement with AskHelpU in ALS, Strengthening its financial structure. 2025 will be decisive for the company, with several major initiatives to accelerate the clinical development of BIO101 (20-Hydroxyecdysone) and its

Read the press release »

JANUARY 27, 2025

Biophytis announces its participation to the BIOMED FORUM investor conference Biophytis announces its participation in the Biomed Forum organized by All Invest Securities on February 4, 2025, in Paris. The Biomed Forum is the annual event dedicated to the healthcare sector, fostering connections between biotech or medtech companies and institutional investors. This will be an opportunity for Biophytis to engage with French and European investors, share updates on the company’s latest developments, and outline its outlook for 2025. Fullscreen Mode

Read the press release »